PL3297654T3 - Leczenie pobariatrycznej hipoglikemii eksendyną (9-39) - Google Patents

Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)

Info

Publication number: PL3297654T3
Authority: PL; Poland
Prior art keywords: exendin; post; treatment; bariatric hypoglycemia; bariatric
Prior art date: 2015-05-22

Application number

PL16800621T

Other languages

English (en)

Inventor

Tracey L. MCLAUGHLIN

Colleen M. CRAIG

Original Assignee

The Board Of Trustees Of The Leland Stanford Junior University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-22

Filing date

2016-05-23

Publication date

2021-12-20

2016-05-23 Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University

2021-12-20 Publication of PL3297654T3 publication Critical patent/PL3297654T3/pl

Links

WSEVKKHALHSUMB-RYVRVIGHSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O WSEVKKHALHSUMB-RYVRVIGHSA-N 0.000 title 1
208000013016 Hypoglycemia Diseases 0.000 title 1
108010024703 exendin (9-39) Proteins 0.000 title 1
230000002218 hypoglycaemic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Diaphragms For Electromechanical Transducers (AREA)

PL16800621T 2015-05-22 2016-05-23 Leczenie pobariatrycznej hipoglikemii eksendyną (9-39) PL3297654T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562165743P	2015-05-22	2015-05-22
US201562254175P	2015-11-11	2015-11-11
US201662329850P	2016-04-29	2016-04-29
EP16800621.1A EP3297654B1 (en)	2015-05-22	2016-05-23	Treatment of post-bariatric hypoglycemia with exendin(9-39)
PCT/US2016/033837 WO2016191395A1 (en)	2015-05-22	2016-05-23	Treatment of post-bariatric hypoglycemia with exendin(9-39)

Publications (1)

Publication Number	Publication Date
PL3297654T3 true PL3297654T3 (pl)	2021-12-20

Family

ID=57393681

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL16800620T PL3297653T3 (pl)	2015-05-22	2016-05-23	Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1
PL16800621T PL3297654T3 (pl)	2015-05-22	2016-05-23	Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL16800620T PL3297653T3 (pl)	2015-05-22	2016-05-23	Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1

Country Status (18)

Country	Link
US (10)	US10639354B2 (pl)
EP (4)	EP3978011B1 (pl)
AU (6)	AU2016267052B2 (pl)
BR (2)	BR112017025000A2 (pl)
CA (2)	CA3024353A1 (pl)
CL (2)	CL2017002913A1 (pl)
CY (2)	CY1124616T1 (pl)
DK (2)	DK3297653T3 (pl)
ES (2)	ES2887723T3 (pl)
HR (2)	HRP20211285T1 (pl)
HU (2)	HUE057301T2 (pl)
LT (2)	LT3297654T (pl)
PL (2)	PL3297653T3 (pl)
PT (2)	PT3297654T (pl)
RS (2)	RS62368B1 (pl)
SI (2)	SI3297654T1 (pl)
SM (2)	SMT202100668T1 (pl)
WO (2)	WO2016191394A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3456340T (lt)	2007-01-08	2022-05-10	The Trustees Of The University Of Pennsylvania	Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
SMT202100668T1 (it)	2015-05-22	2022-01-10	Univ Leland Stanford Junior	Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP7584894B2 (ja)	2016-11-21	2024-11-18	アイガー・バイオファーマシューティカルズ・インコーポレイテッド	エキセンディン（９－３９）の緩衝製剤
US20210030847A1 (en) *	2018-01-23	2021-02-04	Xeris Pharmaceuticals, Inc.	Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
GB201816639D0 (en) *	2018-10-12	2018-11-28	Heptares Therapeutics Ltd	GLP-1 Receptor Antagonist
CA3115527A1 (en) *	2018-10-15	2020-04-23	Eiger Biopharmaceuticals, Inc.	Avexitide for the treatment of hyperinsulinemic hypoglycemia
US20220088144A1 (en) *	2019-01-11	2022-03-24	Universitätsspital Basel	Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) *	2022-08-21	2024-02-29	M. Arkin (1999) Ltd	Glp-1 receptor antagonist and methods of use thereof
WO2024220962A1 (en) *	2023-04-21	2024-10-24	The Board Of Trustees Of The Leland Stanford Junior University	Glp-1r antagonism to improve nutrition following gastrointestinal surgery
WO2025235995A1 (en) *	2024-05-10	2025-11-13	The Board Of Trustees Of The Leland Stanford Junior University	Use of glp-1 receptor agonists alone or in combination with other gastrointestinal hormones that delay gastric emptying for treatment of postbariatric hypoglycemia

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK155694A3 (en)	1992-06-15	1995-05-10	Pfizer	Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en)	1996-08-06	2004-05-13	Yeda Research And Development Co., Ltd	Long-acting exendins and exendin agonists
DE69739172D1 (de)	1996-08-08	2009-01-29	Amylin Pharmaceuticals Inc	Regulation gastrointestinaler beweglichkeit
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
PT1629849E (pt)	1997-01-07	2013-07-09	Amylin Pharmaceuticals Llc	Composições farmacêuticas que compreendem exendinas e seus agonistas
CZ297361B6 (cs)	1998-01-30	2006-11-15	Novo Nordisk A/S	Injekcní stríkacka
ES2233089T3 (es)	1998-12-10	2005-06-01	Agouron Pharmaceuticals, Inc.	Antagonistas no peptidos del receptor de glp-1 y metodos de uso.
EP1658856B1 (en)	1999-01-14	2010-03-17	Amylin Pharmaceuticals, Inc.	Exendins for glucagon suppression
CN101181236A (zh)	1999-01-14	2008-05-21	安米林药品公司	新型exendin激动剂制剂及其给药方法
US6924264B1 (en)	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6903074B1 (en)	1999-06-04	2005-06-07	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.	Neuromedin b and somatostatin receptor agonists
US6495164B1 (en)	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
US6479065B2 (en)	2000-08-10	2002-11-12	Alkermes Controlled Therapeutics, Inc.	Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en)	2001-08-31	2004-11-30	Alkermes Controlled Therapeutics Inc. Ii	Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv)	2000-12-04	2000-12-04	Pharmacia Ab	Novel method and use
WO2002066062A2 (en)	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity
WO2002081649A2 (en)	2001-04-06	2002-10-17	The Trustees Of The University Of Pennsylvania	ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
CN1162446C (zh)	2001-05-10	2004-08-18	上海华谊生物技术有限公司	促胰岛素分泌肽衍生物
GB0113179D0 (en)	2001-05-31	2001-07-25	Novartis Ag	Organic compounds
CA2452044A1 (en)	2001-08-28	2003-03-13	Eli Lilly And Company	Pre-mixes of glp-1 and basal insulin
US7378385B2 (en)	2002-08-08	2008-05-27	University Of Cincinnati	Role for GLP-1 to mediate responses to disparate stressors
US7208514B2 (en)	2003-03-13	2007-04-24	Mitsubishi Pharma Corporation	Tumorigenesis inhibitor
PT1687019T (pt)	2003-11-20	2018-02-26	Novo Nordisk As	Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
US7456254B2 (en)	2004-04-15	2008-11-25	Alkermes, Inc.	Polymer-based sustained release device
PL2409707T3 (pl)	2004-04-15	2015-08-31	Amylin Pharmaceuticals Llc	Urządzenie o przedłużonym uwalnianiu na bazie polimeru
DE102004043153B4 (de)	2004-09-03	2013-11-21	Philipps-Universität Marburg	Erfindung betreffend GLP-1 und Exendin
CN101217940B (zh)	2005-06-06	2013-03-27	卡穆鲁斯公司	Glp-1类似物制剂
LT2347762T (lt)	2005-08-19	2019-08-26	Amylin Pharmaceuticals, Llc	Eksendinas, skirtas diabeto gydymui ir kūno svorio mažinimui
GEP20125628B (en)	2006-04-21	2012-09-10	Novartis Ag	Pharmaceutical compositions containing antagonist anti-cd40 antibody
AU2007267833B2 (en)	2006-05-26	2012-07-26	Amylin Pharmaceuticals, Llc	Composition and methods for treatment of congestive heart failure
LT3456340T (lt)	2007-01-08	2022-05-10	The Trustees Of The University Of Pennsylvania	Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui
EP2144649B1 (de)	2007-04-05	2011-07-20	Tecpharma Licensing AG	Verabreichungsvorrichtung mit funktionalem antriebsglied
DE102007016811A1 (de)	2007-04-05	2008-10-09	Tecpharma Licensing Ag	Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
CA2683610C (en)	2007-04-23	2013-01-08	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
EP2300031B1 (en)	2008-05-05	2017-09-20	Oramed Ltd.	Methods and compositions for oral administration of exenatide
WO2009143285A2 (en)	2008-05-21	2009-11-26	Amylin Pharmaceuticals, Inc.	Exendins to lower cholestrol and triglycerides
WO2009158412A2 (en)	2008-06-25	2009-12-30	Endo Pharmaceuticals Solutions Inc.	Sustained delivery of exenatide and other polypeptides
ES2399651T3 (es)	2008-07-08	2013-04-02	Novartis Ag	Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena
SMT202000405T1 (it)	2008-09-04	2020-09-10	Amylin Pharmaceuticals Llc	Formulazioni a rilascio prolungato usando veicolanti non acquosi
EP2413952B2 (en)	2009-04-03	2019-10-02	Société des Produits Nestlé S.A.	Improvement in promotion of healthy catch-up growth
JP5839597B2 (ja)	2009-06-08	2016-01-06	アムニクスオペレーティングインコーポレイテッド	グルコース調節ポリペプチド並びにその作成及び使用方法
WO2011109787A1 (en)	2010-03-05	2011-09-09	Conjuchem, Llc	Methods of administering insulinotropic peptides
US20130137645A1 (en)	2010-07-19	2013-05-30	Mary S. Rosendahl	Modified peptides and proteins
US8969293B2 (en)	2010-12-23	2015-03-03	Rani Therapeutics, Llc	Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140256626A1 (en)	2011-10-18	2014-09-11	Prolynx Llc	Peg conjugates of exenatide
WO2013120022A2 (en)	2012-02-08	2013-08-15	Seneb Biosciences, Inc.	Treatment of hypoglycemia
EP4527855A3 (en)	2012-03-26	2025-06-11	Sanofi	Stable igg4 based binding agent formulations
WO2015022420A1 (en)	2013-08-16	2015-02-19	Medimmune Limited	Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
SMT202100668T1 (it)	2015-05-22	2022-01-10	Univ Leland Stanford Junior	Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP7584894B2 (ja)	2016-11-21	2024-11-18	アイガー・バイオファーマシューティカルズ・インコーポレイテッド	エキセンディン（９－３９）の緩衝製剤
AU2023320411A1 (en)	2022-08-05	2025-01-30	Indiana University Research And Technology Corporation	Glucagon-like peptide-1 receptor antagonists

2016
- 2016-05-23 SM SM20210668T patent/SMT202100668T1/it unknown
- 2016-05-23 LT LTEPPCT/US2016/033837T patent/LT3297654T/lt unknown
- 2016-05-23 WO PCT/US2016/033836 patent/WO2016191394A1/en not_active Ceased
- 2016-05-23 RS RS20211073A patent/RS62368B1/sr unknown
- 2016-05-23 PT PT168006211T patent/PT3297654T/pt unknown
- 2016-05-23 PL PL16800620T patent/PL3297653T3/pl unknown
- 2016-05-23 SM SM20210488T patent/SMT202100488T1/it unknown
- 2016-05-23 AU AU2016267052A patent/AU2016267052B2/en active Active
- 2016-05-23 SI SI201631300T patent/SI3297654T1/sl unknown
- 2016-05-23 EP EP21194982.1A patent/EP3978011B1/en active Active
- 2016-05-23 BR BR112017025000-4A patent/BR112017025000A2/pt not_active Application Discontinuation
- 2016-05-23 RS RS20211458A patent/RS62627B1/sr unknown
- 2016-05-23 DK DK16800620.3T patent/DK3297653T3/da active
- 2016-05-23 PL PL16800621T patent/PL3297654T3/pl unknown
- 2016-05-23 US US15/576,647 patent/US10639354B2/en active Active
- 2016-05-23 US US15/576,646 patent/US10660937B2/en active Active
- 2016-05-23 AU AU2016267057A patent/AU2016267057B2/en active Active
- 2016-05-23 CA CA3024353A patent/CA3024353A1/en active Pending
- 2016-05-23 EP EP16800620.3A patent/EP3297653B1/en active Active
- 2016-05-23 ES ES16800621T patent/ES2887723T3/es active Active
- 2016-05-23 SI SI201631362T patent/SI3297653T1/sl unknown
- 2016-05-23 HU HUE16800620A patent/HUE057301T2/hu unknown
- 2016-05-23 HU HUE16800621A patent/HUE055728T2/hu unknown
- 2016-05-23 EP EP21176474.1A patent/EP3936143A1/en active Pending
- 2016-05-23 HR HRP20211285TT patent/HRP20211285T1/hr unknown
- 2016-05-23 HR HRP20211768TT patent/HRP20211768T1/hr unknown
- 2016-05-23 DK DK16800621.1T patent/DK3297654T3/da active
- 2016-05-23 CA CA3024358A patent/CA3024358A1/en active Pending
- 2016-05-23 WO PCT/US2016/033837 patent/WO2016191395A1/en not_active Ceased
- 2016-05-23 BR BR112017024997-9A patent/BR112017024997A2/pt not_active Application Discontinuation
- 2016-05-23 EP EP16800621.1A patent/EP3297654B1/en active Active
- 2016-05-23 LT LTEPPCT/US2016/033836T patent/LT3297653T/lt unknown
- 2016-05-23 ES ES16800620T patent/ES2897955T3/es active Active
- 2016-05-23 PT PT16800620T patent/PT3297653T/pt unknown
2017
- 2017-11-16 CL CL2017002913A patent/CL2017002913A1/es unknown
- 2017-11-16 CL CL2017002911A patent/CL2017002911A1/es unknown
2020
- 2020-03-09 US US16/813,535 patent/US10993991B2/en active Active
- 2020-03-09 US US16/813,536 patent/US10993992B2/en active Active
2021
- 2021-04-09 US US17/226,164 patent/US11617782B2/en active Active
- 2021-04-09 US US17/226,161 patent/US11622995B2/en active Active
- 2021-09-01 CY CY20211100779T patent/CY1124616T1/el unknown
- 2021-11-29 CY CY20211101046T patent/CY1125147T1/el unknown
2022
- 2022-03-22 AU AU2022201973A patent/AU2022201973B2/en active Active
- 2022-04-14 AU AU2022202506A patent/AU2022202506B2/en active Active
2023
- 2023-02-22 US US18/172,543 patent/US12220444B2/en active Active
- 2023-02-22 US US18/172,546 patent/US12102663B2/en active Active
2024
- 2024-06-17 US US18/745,091 patent/US20250082730A1/en active Pending
2025
- 2025-01-02 US US19/008,248 patent/US20250255935A1/en active Pending
- 2025-08-13 AU AU2025217292A patent/AU2025217292A1/en active Pending
- 2025-08-22 AU AU2025220813A patent/AU2025220813A1/en active Pending

Also Published As

Publication number	Publication date
US20240000894A1 (en)	2024-01-04
US10993992B2 (en)	2021-05-04
SI3297654T1 (sl)	2021-11-30
RS62368B1 (sr)	2021-10-29
CA3024358A1 (en)	2016-12-01
WO2016191394A1 (en)	2016-12-01
EP3297654B1 (en)	2021-07-07
SMT202100488T1 (it)	2021-11-12
HUE055728T2 (hu)	2021-12-28
US20230346890A1 (en)	2023-11-02
AU2022201973B2 (en)	2025-05-15
PL3297653T3 (pl)	2022-01-31
US11622995B2 (en)	2023-04-11
AU2016267057B2 (en)	2021-12-23
US20210290731A1 (en)	2021-09-23
EP3297653A1 (en)	2018-03-28
AU2016267052B2 (en)	2022-01-20
AU2016267052A1 (en)	2017-12-14
EP3978011A1 (en)	2022-04-06
EP3936143A1 (en)	2022-01-12
US12102663B2 (en)	2024-10-01
BR112017024997A2 (pt)	2018-07-31
DK3297653T3 (da)	2021-10-18
AU2022202506A1 (en)	2022-05-12
US10993991B2 (en)	2021-05-04
CA3024353A1 (en)	2016-12-01
CL2017002913A1 (es)	2018-06-01
US20250255935A1 (en)	2025-08-14
US20180147261A1 (en)	2018-05-31
PT3297653T (pt)	2021-10-25
US12220444B2 (en)	2025-02-11
ES2887723T3 (es)	2021-12-27
US20250082730A1 (en)	2025-03-13
EP3297654A1 (en)	2018-03-28
CY1125147T1 (el)	2023-03-24
LT3297654T (lt)	2021-10-25
US10660937B2 (en)	2020-05-26
AU2025217292A1 (en)	2025-09-04
HUE057301T2 (hu)	2022-05-28
EP3297653A4 (en)	2018-12-26
SMT202100668T1 (it)	2022-01-10
EP3978011B1 (en)	2026-05-06
AU2022202506B2 (en)	2025-06-05
AU2022201973A1 (en)	2022-04-14
DK3297654T3 (da)	2021-09-06
EP3297653B1 (en)	2021-09-15
US11617782B2 (en)	2023-04-04
WO2016191395A1 (en)	2016-12-01
US20200276272A1 (en)	2020-09-03
US20210315974A1 (en)	2021-10-14
AU2016267057A1 (en)	2017-12-14
RS62627B1 (sr)	2021-12-31
PT3297654T (pt)	2021-09-06
BR112017025000A2 (pt)	2018-08-07
HRP20211285T1 (hr)	2022-01-07
US20200276271A1 (en)	2020-09-03
ES2897955T3 (es)	2022-03-03
US10639354B2 (en)	2020-05-05
US20180117122A1 (en)	2018-05-03
EP3297654A4 (en)	2018-04-11
HRP20211768T1 (hr)	2022-02-18
LT3297653T (lt)	2022-01-10
SI3297653T1 (sl)	2022-01-31
AU2025220813A1 (en)	2025-09-11
CL2017002911A1 (es)	2018-05-25
CY1124616T1 (el)	2022-07-22

Publication	Publication Date	Title
SMT202100488T1 (it)	2021-11-12	Trattamento dell'ipoglicemia post-bariatrica con exendina(9-39)
SG10202100803WA (en)	2021-03-30	Endoscope with pannable camera and related method
ZA201706059B (en)	2023-08-30	Method of treatment with tradipitant
GB201502137D0 (en)	2015-03-25	Treatment
IL252803B (en)	2022-04-01	Formulation with a constant ratio of insulin glargine/licisanitide
GB201522243D0 (en)	2016-01-27	Treatment
GB201519450D0 (en)	2015-12-16	Novel treatment
IL254500A0 (en)	2017-11-30	Treatment of patients with type 2 diabetes
GB201508841D0 (en)	2015-07-01	Treatment
SI3139948T1 (sl)	2020-07-31	Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21
GB201503008D0 (en)	2015-04-08	Treatment
IL247218A0 (en)	2016-09-29	Treatment of infections caused by h. pylori using mtan inhibitors
GB201513543D0 (en)	2015-09-16	Compositions for use in the treatment of diabetes
GB201414366D0 (en)	2014-09-24	Blood defence
AU2015904246A0 (en)	2015-11-05	Treatment of diabetes
PT3139948T (pt)	2020-05-22	Tratamento de diabetes usando glp-1 e anti-il-21
AU2016901862A0 (en)	2016-06-02	Treatment of diabetes
GB201513922D0 (en)	2015-09-23	Treatment of hyperpigmentation
GB201518349D0 (en)	2015-12-02	Treatment
GB201515739D0 (en)	2015-10-21	Treatment
GB201514008D0 (en)	2015-09-23	Treatment
GB201604099D0 (en)	2016-04-20	Insulin biosensor
AU2015902668A0 (en)	2015-07-16	Fast acting hypoglycaemic treatment ( Hypo-fast)
EP3093013A4 (en)	2017-09-13	Agent for treating diabetes
GB201407396D0 (en)	2014-06-11	Confectionary treatment